Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Bevacizumab + HAIC for Metastatic Liver Cancer
NCT05643417Phase 1Unknown
- Sponsor
- Fudan University
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab in liver cancer (9 arms), sponsored by Fudan University. Primary endpoints: Incidence and degree of Adverse Events and Serious Adverse Events at 24 months and Objective Response Rate at 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT05643417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643417.